How compounded tirzepatide works: the dual GIP/GLP-1 mechanism

One molecule, two doorbells, one larger fullness signal.

TL;DR

• Tirzepatide activates two gut hormone receptors at once: GLP-1 and GIP. Both shape appetite, gastric emptying, and insulin release.
• The branded products Mounjaro and Zepbound are FDA-approved; compounded tirzepatide is prepared by state-licensed 503A pharmacies from FDA-approved active pharmaceutical ingredients and is itself not FDA-approved.
• The mechanism is the same molecule. The legal status, manufacturing path, and oversight are not.

What it is

Tirzepatide is a single peptide molecule designed to bind two receptors at once: GLP-1 (in plain English: glucagon-like peptide-1, a gut hormone released after meals that signals fullness) and GIP (in plain English: glucose-dependent insulinotropic polypeptide, another gut hormone that helps regulate insulin and fat storage). Branded tirzepatide is manufactured by Eli Lilly as Mounjaro and Zepbound. Compounded tirzepatide is prepared by 503A pharmacies from FDA-approved tirzepatide active pharmaceutical ingredient and is itself not FDA-approved (FDA, 2024).

How it works

Picture two doorbells on the same front door. Press one (GLP-1) and the kitchen lights up — the brain registers fullness, the stomach empties slower, and the pancreas releases insulin in response to a meal. Press both (GLP-1 and GIP) and a second set of cues joins in, including signals that influence how the body stores and releases fat. Tirzepatide presses both bells with one molecule. That dual activation is the published distinction from single-receptor GLP-1 medicines (Coskun et al., Cell Metab, 2018, and SURMOUNT trial program, 2022).

Who asks about it

People usually arrive at this question after deciding tirzepatide might be a fit and wanting to understand what it actually does in the body — beyond the headlines. The answer matters because the mechanism shapes the side effect profile and the conversation a clinician will have about dose escalation.

What the research says

In the SURMOUNT trial program, tirzepatide produced larger average weight reductions than placebo in adults with obesity. The dual mechanism is consistent across the published evidence base. Compounded tirzepatide products have not been studied head-to-head against branded tirzepatide; safety and consistency depend on the specific compounding pharmacy. Compounded GLP-1 and GIP/GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb 2026).

What to know before considering it

Tirzepatide carries a warning for thyroid C-cell tumors based on rodent studies and is not for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Common side effects include nausea, gastrointestinal symptoms, injection-site reactions, and reduced appetite. Compounded tirzepatide requires a licensed clinician’s prescription and ongoing monitoring.

The Halftime POV

Mechanism is one part of the conversation. Source, oversight, and clinician relationship are the rest. Compounded tirzepatide is a real category with real evidence on the molecule and a far thinner record on any given pharmacy’s product. Pick the clinician first, then the protocol.

Related reading:

• Compounded tirzepatide: what this dual agonist actually is
• GLP-1: what this gut hormone actually does
• How semaglutide activates GLP-1 receptors: the mechanism

FAQ

Q: How does tirzepatide work? A: Tirzepatide activates two gut-hormone receptors at once — GLP-1 and GIP. Both receptors influence appetite, gastric emptying, and how the pancreas releases insulin. The dual activation is what distinguishes tirzepatide from single-receptor GLP-1 medicines like semaglutide.

Q: How is compounded tirzepatide different from Mounjaro or Zepbound? A: Mounjaro and Zepbound are FDA-approved branded tirzepatide products from Eli Lilly with specific approved uses (type 2 diabetes and chronic weight management, respectively). Compounded tirzepatide is prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and is itself not FDA-approved. The branded products are manufactured under FDA-inspected facilities; compounded versions vary by pharmacy.

Q: Is compounded tirzepatide safe? A: Tirzepatide as an active pharmaceutical ingredient has a published safety profile from the SURPASS and SURMOUNT trials of the branded product. Compounded tirzepatide quality depends on the pharmacy. Side effects are common and include nausea, gastrointestinal symptoms, and injection-site reactions. Compounded tirzepatide is the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb 2026) and FDA enforcement attention.

Disclaimer

This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Coskun T, et al. LY3298176, a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist for type 2 diabetes. Cell Metabolism, 2018; SURMOUNT-1 results, NEJM, 2022.
• FDA. Mounjaro (tirzepatide) information.